100 related articles for article (PubMed ID: 12925510)
1. A statistical measure of tissue heterogeneity with application to 3D PET sarcoma data.
O'Sullivan F; Roy S; Eary J
Biostatistics; 2003 Jul; 4(3):433-48. PubMed ID: 12925510
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of tumor shape into an assessment of spatial heterogeneity for human sarcomas imaged with FDG-PET.
O'Sullivan F; Roy S; O'Sullivan J; Vernon C; Eary J
Biostatistics; 2005 Apr; 6(2):293-301. PubMed ID: 15772107
[TBL] [Abstract][Full Text] [Related]
3. Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome.
Eary JF; O'Sullivan F; O'Sullivan J; Conrad EU
J Nucl Med; 2008 Dec; 49(12):1973-9. PubMed ID: 18997052
[TBL] [Abstract][Full Text] [Related]
4. A statistical modeling approach to the analysis of spatial patterns of FDG-PET uptake in human sarcoma.
O'Sullivan F; Wolsztynski E; O'Sullivan J; Richards T; Conrad EU; Eary JF
IEEE Trans Med Imaging; 2011 Dec; 30(12):2059-71. PubMed ID: 21724502
[TBL] [Abstract][Full Text] [Related]
5. Fluorodeoxyglucose positron emission tomography scanning: basic principles and imaging of adult soft-tissue sarcomas.
Conrad EU; Morgan HD; Vernon C; Schuetze SM; Eary JF
J Bone Joint Surg Am; 2004; 86-A Suppl 2():98-104. PubMed ID: 15691114
[No Abstract] [Full Text] [Related]
6. PET-MR image fusion in soft tissue sarcoma: accuracy, reliability and practicality of interactive point-based and automated mutual information techniques.
Somer EJ; Marsden PK; Benatar NA; Goodey J; O'Doherty MJ; Smith MA
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):54-62. PubMed ID: 12483410
[TBL] [Abstract][Full Text] [Related]
7. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma.
Eary JF; Conrad EU; Bruckner JD; Folpe A; Hunt KJ; Mankoff DA; Howlett AT
Clin Cancer Res; 1998 May; 4(5):1215-20. PubMed ID: 9607579
[TBL] [Abstract][Full Text] [Related]
8. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis.
Eary JF; O'Sullivan F; Powitan Y; Chandhury KR; Vernon C; Bruckner JD; Conrad EU
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1149-54. PubMed ID: 12192559
[TBL] [Abstract][Full Text] [Related]
9. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.
Folpe AL; Lyles RH; Sprouse JT; Conrad EU; Eary JF
Clin Cancer Res; 2000 Apr; 6(4):1279-87. PubMed ID: 10778952
[TBL] [Abstract][Full Text] [Related]
10. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma.
Johnson GR; Zhuang H; Khan J; Chiang SB; Alavi A
Clin Nucl Med; 2003 Oct; 28(10):815-20. PubMed ID: 14508272
[TBL] [Abstract][Full Text] [Related]
11. PET for sarcomas other than gastrointestinal stromal tumors.
Toner GC; Hicks RJ
Oncologist; 2008; 13 Suppl 2():22-6. PubMed ID: 18434635
[TBL] [Abstract][Full Text] [Related]
12. [18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation.
Buchmann I; Vogg AT; Glatting G; Schultheiss S; Möller P; Leithäuser F; Schulte M; Gfrörer W; Kotzerke J; Reske SN
Cancer Biother Radiopharm; 2003 Jun; 18(3):327-37. PubMed ID: 12954120
[TBL] [Abstract][Full Text] [Related]
13. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography-based assessment of metabolic gradient and other prognostic features in sarcoma.
Wolsztynski E; O'Sullivan F; Keyes E; O'Sullivan J; Eary JF
J Med Imaging (Bellingham); 2018 Apr; 5(2):024502. PubMed ID: 29845091
[TBL] [Abstract][Full Text] [Related]
15. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in sarcomas].
Bourguet P;
Bull Cancer; 2003 Feb; 90 Spec No():S96-102. PubMed ID: 12739341
[No Abstract] [Full Text] [Related]
16. Imaging and response in soft tissue sarcomas.
Schuetze SM
Hematol Oncol Clin North Am; 2005 Jun; 19(3):471-87, vi. PubMed ID: 15939192
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography.
Lucas JD; O'Doherty MJ; Cronin BF; Marsden PK; Lodge MA; McKee PH; Smith MA
Br J Surg; 1999 Apr; 86(4):550-6. PubMed ID: 10215835
[TBL] [Abstract][Full Text] [Related]
18. Role of PET/PET-CT in the management of sarcomas.
Kumar R; Chauhan A; Vellimana AK; Chawla M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1241-50. PubMed ID: 16925490
[TBL] [Abstract][Full Text] [Related]
19. [Biologic characterization of soft tissue sarcomes by positron emission tomography (initial results)].
Schwarzbach M; Willeke F; Dimitrakopoulou-Strauss A; Strauss LG; Mechtersheimer G; Hinz U; Lehnert T; Herfarth C
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):635-9. PubMed ID: 14518332
[TBL] [Abstract][Full Text] [Related]
20. [Optimization of PET image quality by means of 3D data acquisition and iterative image reconstruction].
Doll J; Zaers J; Trojan H; Bellemann ME; Adam LE; Haberkorn U; Brix G
Nuklearmedizin; 1998 Mar; 37(2):62-7. PubMed ID: 9547752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
